Bristol-Myers Squibb Company (BMY) is owned by a number of high-value investors. Its largest direct holder is Sandra Leung Executive Vice President and General Counsel with 546,080 shares. The second-largest direct holder is Charles A. Bancroft Chief Financial Officer and Executive Vice President, Global Business Operations, with 395,994 shares of the company’s stock. In third place with 368,066 shares of BMY is Giovanni Caforio Chairman of the Board and Chief Executive Officer.
Now turning to institutional ownership of Bristol-Myers Squibb Company (BMY), The Vanguard Group, Inc. is the top holder with 132.11 million shares. The next largest fund holder of this company’s stock is Wellington Management Co. LLP with 109.66 million shares. In the third-place spot with 77.27 million shares is BlackRock Fund Advisors.
This company’s stock price was $57.75 at the previous market close, with its latest volume reaching 16228203. Compare that to its average daily volume of 15.54M. Given the fact that this stock has 2.37B shares outstanding, its current market value is sitting at $136.95B. This publicly-traded stock’s 60-month Beta is 0.68. Its Price to Sales ratio is 5.67, its Price to Cash Flow ratio is 4.21, and its Price to Book ratio is 5.34.
BMY stock has achieved a 5-day range of $56.68 to $58.10, with a total performance of +1.80% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $55.30 to $59.17, generating a +1.03% change during the period. In the past three months, this stock’s price has changed by +20.21%, trading in the range of $47.49 to $59.17.
In the past 5 days, shares of BMY have made a new high 2 times. In the last month, it has made a new high 6 times, and in the past 3 months, it has made a new high 22 times.
Now let’s turn to this public company’s earnings. For the quarter ending 9/29/2019, the earnings per share (EPS) was reported at 1.17. This is a 0.1 difference compared to the consensus estimate of 1.07, amounting to an earnings surprise of 9.30%. In the previous quarter, which ended in 9/29/2019, the consensus estimate was 1.06, making for an earnings surprise of 11.30%. For the quarter ending 3/30/2019, EPS was reported at 1.1, generating a 0.90% earnings surprise.
The Net Income for the most recent full fiscal year, which ended in 12-2018, was $4.95 billion. This is compared to the prior year, where Net Income was $975.0 million. Meanwhile, this company’s Operating Cash Flow was $5.94 billion for the year, compared to $5.28 billion in 2017. Capital Expenditures for the year were reportedly -$951.0 million, compared to -$1.05 billion, and Free Cash flow was $4.99 billion compared to the prior year’s $4.22 billion.
Bristol-Myers Squibb Company (BMY) stock currently has a Financial Strength score of 6/10. This is due to a combination of factors, including a Cash to Debt ratio of 1.3, an Equity to Asset ratio of 0.31, a Debt to Equity ratio of 1.42 and a Debt to EBITDA of 3.24. The Interest Coverage of this stock is 16.29, its Piotroski F-Score is 7, its Altman Z-Score is 4.37 and its Beneish M-Score is -3.06.
This publicly-traded company’s Profitability and Growth score is 9/10, thanks to a combination of things: an Operating Margin of 28.64, a Net Margin of 23.39, a ROE of 36.92, and a ROC of 141.91.
Shifting focus now to Valuation and Return for BMY, this company’s Price to Tangible Book is 9.28 and its Price to Median PS Value is 0.97. Price to Peter Lynch Fair Value for BMY is now 0.73, and this organization’s Price to Graham Number is 2.62. Meanwhile, its Forward Rate of Return (Yactman) is 23.81.
Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for BMY is sitting at 3.72, while its Current Ratio is 3.83 and its PEG Ratio is 0.9. This stock’s PB Ratio is 5.33, its PS Ratio is 3.92, its Forward PE Ratio is 11.42, and its PE Ratio without NRI is 16.64. Similarly, its Shiller PE Ratio is 24.07, its Price to Owner Earnings is 13.36, its Price to Free Cash Flow is 12.48 and its Price to Operating Cash Flow is 11.18.